JP Morgan Chase
NBIX icon

JP Morgan Chase’s Neurocrine Biosciences NBIX Stock Holding History

JP Morgan Chase’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Buy
81,000
+51,000
+170% +$6.77M ﹤0.01% 2632
2025
Q4 		$4.25M Buy
+30,000
New +$4.35M ﹤0.01% 3471
2025
Q2 		– Sell
-57,000
Closed -$6.3M – 7451
2025
Q1 		$6.3M Hold
57,000
– – ﹤0.01% 2955
2024
Q4 		$7.78M Buy
57,000
+22,000
+63% +$2.72M ﹤0.01% 2941
2024
Q3 		$4.03M Buy
35,000
+5,000
+17% +$685K ﹤0.01% 3373
2024
Q2 		$4.13M Buy
+30,000
New +$4.11M ﹤0.01% 3177
2021
Q3 		– Sell
-25,000
Closed -$2.43M – 6682
2021
Q2 		$2.43M Hold
25,000
– – ﹤0.01% 3655
2021
Q1 		$2.43M Sell
25,000
-16,800
-40% -$1.76M ﹤0.01% 3568
2020
Q4 		$4.01M Buy
+41,800
New +$4.04M ﹤0.01% 2991
2019
Q2 		– Sell
-257,100
Closed -$22.7M – 5915
2019
Q1 		$22.7M Buy
257,100
+212,100
+471% +$17.7M ﹤0.01% 1457
2018
Q4 		$3.21M Buy
+45,000
New +$4.31M ﹤0.01% 2914
2018
Q2 		– Sell
-30,000
Closed -$2.49M – 5629
2018
Q1 		$2.49M Buy
+30,000
New +$2.53M ﹤0.01% 3106
2016
Q3 		– Sell
-32,800
Closed -$1.49M – 4707
2016
Q2 		$1.49M Buy
32,800
+17,800
+119% +$820K ﹤0.01% 2964
2016
Q1 		$593K Buy
+15,000
New +$595K ﹤0.01% 3290

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

JP Morgan Chase's NBIX Position: Q1 2026 in Review

JP Morgan Chase increased its Neurocrine Biosciences (NBIX) stake by 4.6% in Q1 2026, buying an estimated $32.1M and bringing the position to 5,442,067 shares worth $701M. The position accounts for 0.05% of the portfolio, ranked #334.

JP Morgan Chase first reported a position in NBIX in Q2 2013 and has held it in 50 quarters since. The position peaked at $738M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • JP Morgan Chase held 5,442,067 shares of Neurocrine Biosciences worth $701M as of Q1 2026.
  • JP Morgan Chase bought 241,711 Neurocrine Biosciences shares in Q1 2026, an estimated $32.1M.
  • Neurocrine Biosciences made up 0.05% of JP Morgan Chase's portfolio in Q1 2026, its #334 holding.
  • JP Morgan Chase first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 50 quarters since.
  • JP Morgan Chase's Neurocrine Biosciences position peaked at $738M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.